Dr. Vivek Lal
speaker
549 appearances
1 recordings
1 series
first heard Aug 2026
last heard 4 Aug
Dr. Vivek Lal’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Aug 2026 with 1.
Appearances
I did not practice.
No, you know about MMP9.
This is fascinating.
No one knows about this.
I know, it's so important.
And I talk about it, and then I have to deviate from it because people don't know about it.
And it's so important.
guess what increases it the most it's a proteobacteria the bad bugs you know the equalizer everyone you know lipopolysaccharide increases in all our animal models we put a little bit of lps lipopolysaccharide to create the neutrophil inflammation to show that our thing works it is fascinating they've published so much about it in the last 15 years our chief medical officer in our group oh my god so mmp9 is the pathway okay to target
not just for lungs, but also many other inflammatory things.
Throughout the body.
And proteobacteria, the bad bugs, increase this, bad things happen.
Lactobacilli-based formulations like our formulation, RSV-11 strains, specific strains, downregulate the MMP9 pathway, decrease inflammation across the body.
So there are other pathways such as the NF-kappa B pathway.
You know, the NF-kappa B, it's called the inflamazon, right?
It's a pathway which steroid affects the most.
So what we are seeing with these permacules or lactobacilli formulation that we have, it downregulates NF-kappa B pathway also.
Very similar to what steroids would do, but hopefully without the side effects.
NLRP3, that's part of the inflammasome.
It is inflammasome and it's triggered not just by proteobacteria, but by several other molecules.
Like there is something called RAM, there is something called CD44.
Showing 201–220 of 549 · page 11 of 28
← Previous
Next →